



Präsentationen

von Studien der SAKK
und der kooperativen
Gruppen 2023

Konferenz	Art der Präsentation	Studie	Titel	Autoren
ASCO	Poster	DANTE	A randomized, open-label, phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKF-S633/DANTE trial, a trial of AIO in collaboration with SAKK	Al-Batran S, Lorenzen S, Thuss-Patience P C, Homann N, Schenk M, Lindig U, Heuer V, Kretzschmar A, Goekkurt E, Haag G M, Riera Knorrenschild J, Bolling C, Hofheinz R D, Angermeier S, Ettrich T J, Siebenhuener A R, Kopp C, Pauligk C, Götze T O
	Poster	DOMENICA	Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting: DOMENICA study (GINECO-EN105b/ENGOT-en13 study)	Joly F, Ray-Coquard IL, Rubio MJ, Paoletti X, Davis AJ, Hudson E, Lorusso D, Tognon G, Hasler-Strub U, Choi CH, Vardar MA, Lheureux S, Van Gorp T, Shao Peng Tan D, Trillsch F, Eberst L, Lescure C, Hardy-Bessard AC, Chaix M
	Oral presentation	PROSPECT	PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).	Schrag D, Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL, Goldberg J, Al Baghdadi T, Goodman KA, McWilliams RR, Farma JM, George TJ, Kennecke HF, Venook AP, O'Reilly EM, Meyerhardt JA, Dueck AC, Basch E, Chang GJ, Mamon HJ
	Poster	SAKK 16/18	SAKK 16/18: Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III(N2) non-small cell lung cancer (NSCLC). A multicenter phase II trial.	Mauti LA, Finazzi T, Holer L, Bettini A, König D, Frueh M, Haefliger S, Addeo A, Mark MT, Buess M, Froesch P, Janthur WD, Waibel C, Ackermann CJ, Dorn P, Scheibe B, Pless M, Guckenberger M, Savic Prince S, Rothschild S
	Poster	SAKK 19/17	First line (1L) durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17	Mark M, Froesch P, Gysel K, Rothschild SI, Addeo A, Ackermann CJ, Chiquet S, Schneider M, Ribl R, Fischer Maranta A, Bastian S, von Moos R, Joerger M, Früh M
	Poster	SAKK 80/19_Alpine-TIR	Real-world outcomes of patients (pts) with malignant solid tumors treated with immune checkpoint inhibitors (ICI) in relation to smoking status. The SAKK 80/19 SMOKER study.	El Saadany T, Petrusch U, Rojas Mora A, Renner C, Winder T, Benda M, Reimann P, Froesch P, Jakob A, Clavijo Daza A, Müller G, von Moos R, Mark M
ASCO GU	Poster	SAKK 08/15	Phase 2, multicenter, randomized study of salvage radiation therapy +/- metformin for recurrent prostate cancer after radical prostatectomy (SAKK 08/15 – GETUG-AFU 34 PROMET trial)	Dal Pra A, Supiot S, Gysel K, Zilli T, Cathomas R, Reynaud T, Pommier P, Putora PM, Bosetti DG, Guckenberger M, Hildebrandt G, Chiquet S, Brihoum M, Papachristofilou A, Hayoz S, Ghadjar P, Zwahlen DR, Gillissen S, Omlin A, Aebbersold DM

Konferenz	Art der Präsentation	Studie	Titel	Autoren
ASH	Poster	EMCL-Registry	Real World Results of Brexucabtagene Autoleucl for Patients with Relapsed/Refractory Mantle Cell Lymphoma – First German/Swiss Analysis	Hess G, Vucinic V, Rejeski K, Aydilek E, Simon L, Penack O, Koenecke C, von Bonin M, von Tresckow B, Fahr M, Pott C, Stilgenbauer S, Leng C, Schroers R, Duell J, Marks R, Mueller F, Brunnberg U, Kerkhoff A, Ohler A, Wagner Drouet EM, Schmidtman I, Theobald M, Dreyling Martin, Dreger P
	Poster	GRAALL 2014	Exploring the Heterogeneity of Response to Blinatumomab in High-Risk Philadelphia-Negative B-cell Precursor Acute Lymphoblastic Leukemia: An Analysis from the QUEST Sub-study of the GRAALL-2014/B Trial	Boissel N, Huguet F, Leguay T, Hunault M, Kim R, Hicheri Y, Chevallier P, Balsat M, Maury S, Thiebaut A, van Obbergh F, Cluzeau T, Escoffre-Barbe M, Straetmans N, Konopacki J, Belhabri A, Villate A, Pasquier F, Bouscary D, Braun T, Spertini O, Cacheux V, Bonmati C, Wittnebel S, Lhéritier V, Ifrah N, Graux C, Chalandon Y, Clappier E, Dombret H
	Oral presentation	GRAALL 2014	Frontline Consolidation with Nelarabine for Adults with High-risk T-cell Acute Lymphoblastic Leukemia. Results of the GRAALL-2014/T ATRIAL phase 2 study	Boissel N, Graux C, Huguet F, Pasquier F, Touzart A, Cluzeau T, Delabesse E, Chevallier P, Hunault M, Pastoret C, Maury S, Gardel N, Escoffre-Barbe M, Turlure P, Schäfer B, Balsat M, Rousselot P, Leguay T, Jourdan E, Pranger D, Lemasle E, Ronchetti AM, Berceanu A, Caillot D, Uzunov M, Lengliné E, Ifrah N, Chalandon Y, Lhéritier V, Asnafi V, Dombret H
	Oral presentation	GRAALL 2003/2005	NGS-Based Stratification Refines the Risk Stratification in T-ALL and Identifies a Very High-Risk Subgroup of Patients	Simonin M, Vasseur L, Lengline E, Lhermitte L, Cabannes-Hamy A, Balsat M, Schmidt A, Dourthe ME, Touzart A, Graux C, Gardel N, Cayuela JM, Arnoux I, Gandemer V, Huguet F, Ducassou S, Lhéritier V, Chalandon Y, Ifrah N, Dombret H, Macintyre E, Petit A, Rousselot P, Lambert J, Baruchel A, Boissel N, Asnafi V
	Poster	HD 21	Comprehensive analysis of treatment related morbidity and progression-free survival in the GHSG phase III HD21 trial	Borchmann P, Moccia A, Greil R, Schneider G, Hertzberg M, Schaub V, Hüttmann A, Keil F, Dierlamm J, Hänel M, Novak U, Meissner J, Zimmermann A, Jathas SM, Zijlstra JM, Fossa A, Viardot A, Hertenstein B, Martin S, Giri P, Kamper P, Molin D, Kreissl S, Ferdinandus J, Fuchs M, Rosenwald A, Klapper W, Eich H, Baues C, Hallek M, Dietlein M, Kobe C, Diehl V
	Oral presentation	SAKK 35/10	Long-Term Efficacy of a 6-Month Regimen of Rituximab and Lenalidomide in Follicular Lymphoma Patients in Need of First Therapy: Updated Analysis of the SAKK35/10 Randomized Trial	Zucca, E, Schär S, Vanazzi A, Østenstad B, Mey, U, Rauch D, Wahlin BE, Hitz F, Hernberg M, Johansson AS, deNully Brown P, Hagberg H, Ferreri, AJM, Krasniqi, F, Voegeli M, Novak U, Zander T, Bersvendsen H, Mamot, C, Mingrone W, Stathis A, Dirnhofer S, Hayoz S, Kimby E
CEN	Oral presentation	SAKK 80/19_Alpine-TIR	Rule-based estimation of lines of therapy (LoT) from oncological registry data: the SAKK 80/19 AlpineTIR registry	Rojas Mora A, Stepniewski C, Petrusch U, Hayoz S

Konferenz	Art der Präsentation	Studie	Titel	Autoren
DGU	Poster	SAKK 01/18	SAKK 01/18: Deeskalierte Radiochemotherapie beim Seminom Stadium IIA/B	Bedke J, Müller A-C, Schär C, Cathomas R, Papachristofilou A
EANM	Oral presentation	SAKK 09/10	Implementation of PSMA-PET/CT improves treatment outcomes after salvage radiotherapy for recurrent or persistent prostate cancer after surgery	Zamboglou C, Staus P I, Wolkewitz M, Schmidt Hegemann N, Wiegel T, Emmett L, Fanti S, Grosu A L, Koerber S, Kroeze S, Ceci F, Peeken J, Hayoz S, Aebersold D M, Vrachimis A, Ghadjar P
EAU	Poster	SAKK 06/17	Surgical safety and quality of radical cystectomy and pelvic lymph node dissection after neoadjuvant Durvalumab and Cisplatin/Gemcitabine for muscle invasive bladder cancer: results from the SAKK 06/17 phase II study	Afferi L, Spahn M, Hayoz S, Strebel RT, Rothschild SI, Seifert H, Ozdemir BC, Kiss B, Maletzki P, Engeler D, Wirth G, Hadaschik B, Lucca I, John H, Sauer A, Muntener M, Schneider M, Musilova J, Petrusch U, Cathomas R
EHA	Poster	HOVON 103	Real-World Data as supplementary controls for the prospective randomized HOVON-103 trial in intensively treated elderly acute myeloid leukemia patients	Hermans SJF, van Norden Y, van Werkhoven ED, Dinmohamed AG, Huijgens PC, Ossenkoppele GJ, Huls GA, Löwenberg B, Pabst T, Breems DA, Postmus D, Pignatti F, Versluis J, Cornelissen JJ
	Poster	HOVON 132	Emerging leukemia associated immunophenotypes (LAIPs) after intensive chemotherapy in bone marrow of acute myeloid leukemia patients	Ngai LL, Hanekamp D, Kelder A, Scholten W, Carbaat-Ham J, Snel AN, Bachas C, Tettero JM, van der Velden VHJ, Slomp J, Hobo W, Breems DA, Fischer T, Gjertsen BT, Griskevicius L, Juliusson G, Maertens JA, Manz MG, Pabst T, Passweg JR, Porkka K, Valk PJ, Gradowska P, Löwenberg B, de Leeuw DC, Van de Loosdrecht AA, Ossenkoppele GJ, Cloos J
	Poster	HOVON 132	Validation of limit of quantification approach based flow cytometry for measurable residual disease assessment in acute myeloid leukemia in the HOVON-SAKK-132 trial	Tettero JM, Palmieri R, Ngai LL, Bachas C, Breems DA, Fischer T, Gjertsen BT, Griskevicius L, Juliusson G, Kelder A, Maertens J, Manz MG, Pabst T, Passweg J, Porkka K, Löwenberg B, Venditti A, Ossenkoppele GJ, Buccisano F, Cloos J
	Poster	HOVON cross-trials analysis	Prognostic significance of measurable residual disease detection by flow cytometry in autologous stem cell apheresis products of patients with AML	Tettero JM, Buisman Y, Ngai LL, Bachas C, Gjertsen BT, Kelder A, van de Loosdrecht AA, Manz MG, Pabst T, Scholten W, Ossenkoppele GJ, Cloos J, de Leeuw DC
ELCC	Poster	SAKK 16/14	SAKK 16/14: Immune profiling of pre-operative biopsies correlates with survival and immune activation in stage IIIA(N2) NSCLC after neoadjuvant immunotherapy	Rothschild SI, Sobottka B, Tochtermann F, Trueb M, Nowak M, Alborelli I, Leonards K, Manzo M, Keller E, Herzig P, Schmid D, Hayoz S, Chiquet S, Schneider M, Pless M, Jermann P, Zippelius A, Spasenija Savic Prince S, Koelzer VH
ESMO	Poster	SAKK services	Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: a prospective single center study with inpatient comparison	Johnson K, Stoffel B, Schwitter M, Hayoz S, Rojas Mora A, Richter P, Fischer A, El Saadany T, Hasler U, von Moos R, Patzen A, Mark M, Roberts G, Cathomas R

Konferenz	Art der Präsentation	Studie	Titel	Autoren
ESMO	Poster		Real-world outcomes of patients with malignant pleural mesothelioma (MPM) treated with combination nivolumab and ipilimumab in the first- or later line setting	Schmid S, Holer L, Frueh M, Koster KL, Rothschild S, Britschgi C, Boos L, Frehner L, Cardoso Almeida S, Metaxas Y, Mark M, Froesch P, Janthur WD, Allemann AT, Waibel C, Vonder Mühl-Schill C, Cerciello F, Mauti L
	Oral presentation	ENGOT-en7_AtTEnd	Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma	Colombo N, Harano K, Hudson E, Galli F, Antill Y, Choi CH, Rabaglio M, Marmé F, Petru E, Lai CH, Biagioli E, Fariñas Madrid L, Takehara K, Allan K, Lee YC, Piovano E, Zamagni C, Tasca G, Ferrero A, Barretina Ginesta MP
	Oral presentation	SAKK 11/16	SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & Neck Squamous Cell Carcinoma (R/M HNSCC) patients (pts) progressing after at least one line of systemic therapy treated with MVX-ONCO-1, a cell encapsulation-based immunotherapy.	Mach N, Fernandez E, Vernet R, Von Rohr O, Urwyler M, Charrier E, Belkouch M, Saingier V, Courtout F, De Vito C, Rubin O, Ancrenaz V, Grogg J, Renaux J, Gysel K, Müller G, Brezina T, Rordorf T, Joerger M, Michielin O
	Poster	SAKK 17/18	SAKK 17/18-ORIGIN trial: Efficacy and safety from a multi-center phase II trial of gemcitabine and atezolizumab in patients with advanced NSCLC progressing on immune checkpoint inhibitors	Curioni-Fontecedro A, Holer L, Früh M, Weindler S, König D, Addeo A, Britschgi C, Rigutto A, Waibel C, Bettini A, Cerciello F, Hiltbrunner S, Lynn Nguyen D, Zellweger C, Musilova J, von Moos R, Joerger M
	Poster	SAKK 22/10	Multiplexed immunofluorescence (mIF) to select patients with HER2+ breast cancer (BC) having an excellent outcome without chemotherapy (chemo): a substudy of the PERNETTA trial (SAKK22/10-UCBG-BOOG)	K. Zaman, S. Tissot, F. Benedetti, D. Dietrich, D. Tarussio, J. Huober, H. Bonnefoi, P. Weder, E. Boven, S. Rusakiewicz, L. Kandalajt
	Poster	SAKK 80/19_Alpine-TIR	Are bone targeted agents (BTAs) still useful in times of immunotherapy? The SAKK 80/19 BTA study	Mark M, Rojas Mora A, Winder T, Stathis A, Jakob A, Müller G, Hayoz S, Reimann P, Petrusch U, von Moos R
ICML	Oral presentation	HD 21	BrECADD is non-inferior to eBEACOPP in patients with advanced stage classical Hodgkin Lymphoma: efficacy results of the GHSG phase III HD21 trial	Borchmann P, Moccia A, Greil R, Schneider G, Hertzberg M, Schaub V, Hüttmann A, Keil F, Dierlamm J, Hänel M, Novak U, Meissner J, Zimmermann A, Mathas S, Zijlstra JM, Fossa A, Viardot A, Hertenstein B, Martin S, Giri P, Kamper P, Molin D, Kreissl S, Ferdinandus J, Fuchs M, Rosenwald A, Klapper W, Eich H, Baues C, Hallek M, Dietlein M, Kobe C, Diehl V, Engert A
	Poster	HD 21	Treatment related organ toxicities at one year follow-up in patients with advanced stage classical Hodgkin Lymphoma: results from the randomized phase III HD21 trial by the German Hodgkin Study Group	Ferdinandus J, Moccia A, Greil R, Hertzberg M, Schaub V, Hüttmann A, Keil F, Dierlamm J, Hänel M, Novak U, Meissner J, Zimmermann A, Mathas S, Zijlstra JM, Fossa A, Viardot A, Hertenstein B, Martin S, Giri P, Kamper P, Molin D, Kreissl S, Fuchs M, Behringer K, Schneider G, Rosenwald A, Klapper W, Eich H, Baues C, Hallek M, Dietlein M, Kobe C, Diehl V, Engert A, Borchmann P

Konferenz	Art der Präsentation	Studie	Titel	Autoren
ICML	Oral presentation	HOVON 127/ SAKK 37/16	R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed high risk Burkitt Lymphoma: Final Results of a multi-center randomized Hovon/SAKK Trial	Chamuleau MED, Stenner F, Chitu DA, Novak U, Minnema MC, Geerts P, Stevens WBC, Zenz T, van Imhoff GW, Wu KL, Demandt AMP, Kersten MJ, Terpstra WE, Tick LW, Deeren D, Van Den Neste E, Gregor M, Veelken H, Böhmer LH, Caspar CB, Mutsaers P, Refos JM, Sewsaran R, Fu L, Seefat RL, Uyl-de Groot CA, Dirnhofer S, Van Den Brand M, de Jong D, Nijland M, Lugtenburg P
	Oral presentation	SAKK 35/14	SAKK 35/14 randomized trial of rituximab with or without ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy	Østenstad B, Piroso MC, Schär S, Brodtkorb M, Wahlin BE, Hernberg M, Pedersen M, Stathis A, Zander T, Novak U, Zenz T, Fischer N, Krasniqi F, Hitz F, J Johansson A, Lofgren D, Meyer P, Bjørnevik AT, Hayoz S, Scheibe B, Steiner L, Dirnhofer S, Ceriani L, Zucca E
	Oral presentation	SAKK 38/19	SAKK 38/19: Assessing a ctDNA and PET-oriented therapy in patients with DLBCL A multicenter, open-label, phase II trial	Stathis A, Hitz F, Schär S, Novak U, Fischer N, Mey U, Gritti G, Zander T, Lang N, Cairoli A, Zenz T, Rhyner G, Mingrone W, Schmidt A, Gaidano G, Hohaus S, Stern AQ, Musilova J, Bertoni F, Zucca E, Dirnhofer S, Ceriani L, Rossi D
SABCS	Oral presentation	IBCSG 48-14 POSITIVE	Fertility preservation and assisted reproductive technologies (ART) in breast cancer (BC) patients (pts) interrupting endocrine therapy (ET) to attempt pregnancy	Azim Jr H, Niman S, Partidge A, Demeestere I, Ruggeri M, Colleoni M, Saura C, Shimizu C, Saetersdal A, Kroep J, Mailliez A, Warner E, Borges V, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee J, Walshe J, Ruiz-Borrego M, Moore H, Saunders C, Bjelic-Radicic V, Susnjar S, Cardoso F, Klar N, Spanic T, Ruddy K, Plccart M, Korde L, Goldhirsch A, Gelber R, Pagani O, Peccatori F
	Poster discussion	SAKK 21/12	Final Overall-Survival (OS) analysis of the SAKK 21/12 trial. CR1447 in HR+/HER2- metastatic breast cancer and Androgen receptor positive triple negative breast cancer.	Vetter M, Holer L, Rothgiesser K, Schönfeld W, Riniker S, von Moos R, Trojan A, Kralidis E, Rabaglio M, Fehr MK, Müller A, Thürlimann B
SGBCC	Poster	SAKK 95/17	Impact of the 2020 COVID-19 lockdown in Switzerland on physical activity in patients with early breast cancer under aromatase-inhibitor therapy. A subanalysis of the SAKK 95/17 WISE trial	Hoefnagels N, Gautier A, Müller A, Schär S, Rosset L, Corke Mahbiz N, Schwitter M, Güth U, Jakob A, Balmelli-Cattelan C, Leo C, Fehr M, Thorn DR, Riniker S, Chouiter-Djebaili A, Musilova J, Honecker F
SGU	Oral presentation	SAKK 06/17	Surgical quality and safety of radical cystectomy and pelvic lymph node dissection after neoadjuvant Durvalumab and Cisplatin/Gemcitabine for muscle invasive bladder cancer: results from the trial SAKK 06/17	Afferi L, Spahn M, Hayoz S, Strebel RT, Rothschild SI, Seifert H, Ozdemir BC, Kiss B, Maletzki P, Engeler D, Wirth G, Hadaschik B, Lucca I, John H, Sauer A, Muntener M, Schneider M, Musilova J, Petrusch U, Cathomas R
SOHC	Poster	SAKK services	Prevention of taxane chemotherapy (chemo) induced nail changes and peripheral neuropathy by application of extremity cooling: a prospective single center study with inpatient comparison	Johnson K, Stoffel B, Schwitter M, Hayoz S, Rojas Mora A, Richter P, Fischer A, El Saadany T, Hasler U, von Moos R, Patzen A, Mark M, Roberts G, Cathomas R

Konferenz	Art der Präsentation	Studie	Titel	Autoren
SOHC	Oral presentation	SAKK 19/17	First line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17	Mark M, Froesch P, Gysel K, Rothschild SI, Addeo A, Ackermann CJ, Chiquet S, Schneider M, Ribi R, Fischer Maranta A, Bastian S, von Moos R, Joerger M, Früh M
SOHC	Oral presentation	SAKK 80/19 Alpine-TIR	Real-world outcomes of patients (pts) with malignant solid tumors treated with immune checkpoint inhibitors (ICI) in relation to smoking status. The SAKK 80/19 SMOKER study.	El Saadany T, Petrusch U, Rojas Mora A, Renner C, Winder T, Benda M, Reimann P, Froesch P, Jakob A, Clavijo Daza A, Müller G, von Moos R, Mark M
SSO	Oral presentation	SAKK 23/16	Impact of imaging-guided localization on performance of tailored axillary surgery in patients with clinically node-positive breast cancer: Prospective study within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)	Weber WP, Matrai Z, Hayoz S, Tausch C, Henke G, Zwahlen DR, Gruber G, Zimmermann F, Ackerknecht M, Bjelic-Radisic V, Kurzeder C, Smanyakó V, Meyer I, Müller DJ, Gnant M, Fitzal F, Markellou P, Egle D, Heil J, Knauer M
SSO	Oral presentation	SAKK 23/16	Trends in neoadjuvant systemic therapy rates in Europe: Pre-planned substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)	Weber WP, Matrai Z, Hayoz S, Henke G, Zwahlen DR, Zimmermann F, Ackerknecht M, Meyer I, Leo C, Sarlos D, Dubsky P, Müller DJ, Fehr MK, Gnant M, Fitzal F, Markellou P, Egle D, Heil J, Knauer M, Tausch C
USCAP	Poster	SAKK 75/08	Mutational Screening by Next Generation Sequencing for Response Prediction to Neoadjuvant Therapy and the Identification of Therapeutic Targets in Esophageal Carcinomas – A Translational Study of the SAKK 75/08 Trial.	Vassella E, Holer L, Hayoz S, Perren A, Stahl M, Thuss P, Eisterer W, Mingrone W, Schacher S, Hess V, Ruhstaller T, Langer R
WCLC	Oral presentation	SAKK 16/18	SAKK 16/18: Neoadjuvant chemotherapy, durvalumab and immune-modulatory RT in stage III(N2) NSCLC. Surgical interim analysis.	Dorn P, Holer L, Lardinois D, Dutly A, Karenovics W, Habicht J, Lutz JA, Gelpke H, Opitz I, Haefliger S, König D, Früh M, Addeo A, Vonder Mühl-Schill C, Bettini A, Scheibe B, Savic Prince S, Guckenberger M, Finazzi T, Rothschild SI, Mauti LA